文献速递胸部肿瘤放疗姑息放疗与转移瘤

质子再照射后巩固帕博利珠单抗治疗非小细胞肺癌胸部复发的2期试验

Phase 2 Trial of Consolidation Pembrolizumab After Proton Reirradiation for Thoracic Recurrences of Non-Small Cell Lung Cancer.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2023-08-29

这项2期单臂试验(NCT03087760)评估质子束再照射后巩固帕博利珠单抗用于非小细胞肺癌局限胸腔复发;22例中15例(68%)启动巩固治疗,中位无进展生存8.8个月、总生存22.8个月,≥3级毒性45%,2例5级毒性可能与再照射相关,试验因免疫治疗广泛超方案使用而提前关闭。

要点

  • 22例接受60至70 Gy质子再照射,15例(68%)随后启动巩固帕博利珠单抗,中位3周期。
  • 中位无进展生存8.8个月(95%CI 4.2-23.7),中位总生存22.8个月(95%CI 6.9-未达到)。
  • ≥3级毒性10例(45%),5级毒性2例(主动脉食管瘘6.9个月、咯血46.8个月),均可能与再照射相关。

核心结论

  • 在首个质子和再照射联合巩固免疫治疗的前瞻性试验中,无进展生存可接受、总生存有利。
  • 22例中2例发生晚期5级毒性。
  • 作者认为该方案可考虑用于经选择的非小细胞肺癌孤立胸腔复发患者。

研究设计与样本

  • 2期单臂试验(NCT03087760),入组非小细胞肺癌局限区域复发患者。
  • 完成60至70 Gy质子束再照射后4至12周无疾病进展者接受帕博利珠单抗最长12个月。
  • 主要终点为自再照射开始计算的无进展生存,次要终点为总生存和美国国家癌症研究所不良事件通用术语标准5.0版毒性。
  • 2017年至2021年共22例患者接受质子束再照射。

主要发现

  • 再照射距前次放疗结束中位间隔20个月,91%复发位于中心部位,95%接受同步化疗,77%接受笔形束扫描质子治疗,36%既往接受过度伐利尤单抗。
  • 15例(68%)启动巩固帕博利珠单抗,中位3周期(范围2-17)。
  • 帕博利珠单抗停药最常见原因为毒性(n=5,其中2例与帕博利珠单抗相关)、疾病进展(n=4)和完成1年治疗(n=3)。
  • 中位随访38.7个月,中位无进展生存8.8个月(95%CI 4.2-23.7),中位总生存22.8个月(95%CI 6.9-未达到)。
  • 再照射后仅1例孤立野内失败;≥3级毒性10例(45%),其中2例与帕博利珠单抗相关;5级毒性2例(主动脉食管瘘6.9个月、咯血46.8个月),均可能与再照射相关。

关键数值与推荐

  • 质子束再照射剂量为60至70 Gy。
  • 巩固帕博利珠单抗在再照射完成后4至12周开始,最长12个月。
  • 主要终点无进展生存中位8.8个月(95%CI 4.2-23.7),总生存中位22.8个月(95%CI 6.9-未达到)。
  • ≥3级毒性发生率45%(10/22),5级毒性2例(2/22)。

临床怎么用

  • 作者认为该方案可考虑用于经选择的非小细胞肺癌孤立胸腔复发患者。

局限性

  • 试验因免疫治疗广泛超方案使用而提前关闭。
  • 22例中2例发生晚期5级毒性,均可能与再照射相关。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Reirradiation (reRT) with proton beam therapy (PBT) may offer a chance of cure while minimizing toxicity for patients with isolated intrathoracic recurrences of non-small cell lung cancer (NSCLC). However, distant failure remains common, necessitating strategies to integrate more effective systemic therapy. METHODS AND MATERIALS: This was a phase 2, single-arm trial (NCT03087760) of consolidation pembrolizumab after PBT reRT for locoregional recurrences of NSCLC. Four to 12 weeks after completion of 60 to 70 Gy PBT reRT, patients without progressive disease received pembrolizumab for up to 12 months. Primary endpoint was progression-free survival (PFS), measured from the start of reRT. Secondary endpoints were overall survival (OS) and National Cancer Institute Common Terminology Criteria for Adverse Events, version 5.0 toxicity. RESULTS: Between 2017 and 2021, 22 patients received PBT reRT. Median interval from prior radiation end to reRT start was 20 months. Most recurrences (91%) were centrally located. Most patients received concurrent chemotherapy (95%) and pencil beam scanning PBT (77%), and 36% had received prior durvalumab. Fifteen patients (68%) initiated consolidation pembrolizumab on trial and received a median of 3 cycles (range, 2-17). Pembrolizumab was discontinued most commonly due to toxicity (n = 5; 2 were pembrolizumab-related), disease progression (n = 4), and completion of 1 year (n = 3). Median follow-up was 38.7 months. Median PFS and OS were 8.8 months (95% CI, 4.2-23.7) and 22.8 months (95% CI, 6.9-not reached), respectively. There was only one isolated in-field failure after reRT. Grade ≥3 toxicities occurred in 10 patients (45%); 2 were pembrolizumab-related. There were 2 grade 5 toxicities, an aorto-esophageal fistula at 6.9 months and hemoptysis at 46.8 months, both probably from reRT. The trial closed early due to widespread adoption of immunotherapy off-protocol. CONCLUSIONS: In the first-ever prospective trial combining PBT reRT with consolidation immunotherapy, PFS was acceptable and OS favorable. Late grade 5 toxicity occurred in 2 of 22 patients. This approach may be considered in selected patients with isolated thoracic recurrences of NSCLC.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Yegya-Raman N, Berman AT, Ciunci CA, et al. Phase 2 Trial of Consolidation Pembrolizumab After Proton Reirradiation for Thoracic Recurrences of Non-Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys. 2023. PMID: 37652303. doi:10.1016/j.ijrobp.2023.08.047

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。